At SABCS 2024, Dr. Judy Garber presented the latest 10-year follow-up results from the OlympiA trial, which continue to reinforce the role of adjuvant olaparib in patients with germline BRCA1/2 mutation-associated, high-risk HER2-negative breast cancer. With a median follow-up of 6.1 years (maximum 9.6 years), the trial confirms the long-term benefits of olaparib in reducing recurrence and improving survival outcomes.
The data show significant improvements across key endpoints. The 6-year invasive disease-free survival (IDFS) rate was 9.4% higher in the olaparib group compared to placebo, while the 6-year distant disease-free survival (DDFS) rate improved by 7.8%. Overall survival (OS) also showed a 4.4% increase in the olaparib arm, reaffirming its impact in preventing disease progression and mortality.
Safety remains a critical focus, and the latest findings indicate no new safety concerns with long-term use. The incidence of new primary malignancies was lower in the olaparib group, and there was no evidence of an increased risk of MDS or AML. These results emphasize the continued benefit of genetic testing to identify patients who can benefit from targeted therapy.
With blinded follow-up continuing until June 2029, the OlympiA trial remains a landmark study shaping the treatment landscape for HER2-negative breast cancer. This research stands as a testament to the dedication of investigators, patients, and study partners, and the findings were dedicated to the memory of Dr. Bella Kaufman, who played a key role in the trial’s development.
